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journal homepage: http: / /www.kjms-onl ine.comLETTER TO THE EDITORReversible dasatinib-related pulmonary arterial
hypertension diagnosed by noninvasive
echocardiographyTo the Editor,
Pulmonary arterial hypertension (PAH) is an uncommon
adverse effect of tyrosine kinase inhibitor. The article by
Montani et al. [1] demonstrated PAH in patients treated
with dasatinib. We report a 33-year-old male with chronic
myeloid leukemia who suffered from shortness of breath
after using dasatinib for 63 months. Noninvasive echocar-
diographic assessment revealed reversible PAH corre-
sponding to clinical manifestations.
In October 2013, the patient presented with progressive
dyspnea on exertion. He was known to have chronic phase
chronic myeloid leukemia since January 1998. The initial
laboratory data revealed eosinophilia, basophilia, low
leukocyte alkaline phosphatase score, and positive BCR-ABL
gene. He was initially treated with hydroxyurea 1000 mg
twice per day, and then commenced imatinib at 800 mg/
day since May 2002.
Under imatinib use, hematological complete remission
was achieved, but there was no cytogenetic remission with a
positive b2a2 BCR-ABLmutation. Point mutation in the kinase
domain of BCR-ABL with F359V was identified. Imatinib was
shifted to dasatinib 100 mg/day in July 2008 and a major
molecular response was achieved. However, the patient
suffered from progressive dyspnea in October 2013. The
auscultation showed bilateral clear breathing sound. Promi-
nence of bilateral hilar shadows were present on chest plain
film (Fig. 1A). No thromboembolism evidence existed but
dilatation of pulmonary trunk and proximal arteries in the
chest computed tomography scanwas found (Fig. 1B). Tc-99m
DTPA (Diethylenetriamine pentaacetate) aerosol ventilation
and Tc-99m MMA (microaggregated albulin) perfusion scin-
tigraphy revealed a V (ventilation)/Q (perfusion) match
reduction of the pulmonary functional volume. DopplerConflicts of interest: All authors declare no conflicts of interest.
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arterial hypertension with an estimated pulmonary artery
systolic pressure (PASP) of 105 mmHg, right atrial and right
ventricular dilatation, and severe tricuspid regurgitation
(Fig. 1C and D).We stopped using dasatinib but the symptoms
persisted. One month later, we added on phosphodiesterase
type 5 (PDE 5) inhibitor, sildenafil, and the symptoms
improved gradually. Echocardiography was followed 3months
later and estimated PASP regressed back to 45 mmHg
(Fig. 1E). Dasatinib was replaced by nilotinib in this patient.
Pulmonary arterial hypertension (PAH) is defined as the
mean pulmonary artery pressure (PAP) of >25 mmHg at
rest, or >30 mmHg during exercise [2]. The definite diag-
nosis includes invasive right heart catheterization. Howev-
er, there is a good correlation between transthoracic
echocardiography and right heart catheterization mea-
surement of PASP [3]. PAH is suspected if noninvasive PASP,
determined by tricuspid regurgitation peak gradient (TRPG)
and right atrial pressure(RAP) according to the simplified
Bernoulli equation, is >35 mmHg measured by Doppler
transthoracic echocardiography [2].
In 2007, a study by Quinta´s-Cardama et al. [4] sug-
gested the association between dasatinib and pulmonary
hypertension. In 2012, nine cases of symptomatic pul-
monary hypertension treated with dasatinib have been
identified definitely [1]. PAH appears as a late compli-
cation of dasatinib, occurring after 8e48 months of
exposure [5]. The possible mechanism is dasatinib served
as multi tyrosine kinase inhibitors, including BCR-ABL,
SRC, c-kit, and PDGFR [5]. Symptoms are improved
after discontinuation of dasatinib in the majority of
cases, but some cases require PAH-specific therapy with
sildenafil [5]. In summary, we reported a typical case of
dasatinib-induced PAH diagnosed by noninvasive
echocardiography.y Elsevier Taiwan LLC. All rights reserved.
Figure 1. Characteristic image findings of reversible dasatinib-related pulmonary arterial hypertension. (A and B) Tc-99m DTPA
(diethylenetriamine pentaacetate) aerosol ventilation and Tc-99m MMA (microaggregated albulin) perfusion scintigraphy reveals
V (ventilation)/Q (perfusion) match reduction of pulmonary functional volume; (C and D) Doppler transthoracic echocardiography
shows severe pulmonary arterial hypertension with estimated PASP 105 mmHg; (E); after stopping dasatinib and adding sildenafil,
the estimated PASP fell back to 45 mmHg. PASP Z pulmonary artery systolic pressure.
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